Caronna, EJosé Gallardo, VAlpuente, ATorres-Ferrus, MSánchez-Mateo, N MViguera-Romero, JLópez-Veloso, A CLópez-Bravo, AGago-Veiga, A BIrimia Sieira, PPorta-Etessam, JSantos-Lasaosa, SPozo-Rosich, PSpanish CGRP-COVID Study Group2025-01-072025-01-072021https://hdl.handle.net/10668/24374CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P=.320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Anticuerpos monoclonalesCGRPCOVID-19MigraineMigrañaMonoclonal antibodiesSARS-CoV-2Antibodies, MonoclonalCOVID-19Calcitonin Gene-Related PeptideCross-Sectional StudiesFemaleHumansMiddle AgedMigraine DisordersPandemicsSARS-CoV-2research article34654536open access10.1016/j.nrleng.2021.03.0052173-5808PMC8506139https://doi.org/10.1016/j.nrleng.2021.03.005https://pmc.ncbi.nlm.nih.gov/articles/PMC8506139/pdf